Free Trial

Cardiff Oncology Q1 2024 Earnings Report

Cardiff Oncology logo
$3.06 -0.08 (-2.55%)
As of 04/1/2025 04:00 PM Eastern

Cardiff Oncology EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Cardiff Oncology Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.11 million
Beat/Miss
Beat by +$100.00 thousand
YoY Revenue Growth
N/A

Cardiff Oncology Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Cardiff Oncology Earnings Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
Cardiff Oncology price target raised to $17 from $13 at H.C. Wainwright
Piper Sandler Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)
See More Cardiff Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email.

About Cardiff Oncology

Cardiff Oncology (NASDAQ:CRDF), a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

View Cardiff Oncology Profile

More Earnings Resources from MarketBeat